Developing an HIV vaccine

In 2015, 17 million HIV-infected individuals worldwide were on antiretroviral drug therapies, which are remarkably effective in suppressing the virus. Yet, 6000 people a day became newly infected, making the quest for an effective and safe HIV vaccine a major global priority. However, developing a v...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2017-03, Vol.355 (6330), p.1129-1130
Main Authors: Haynes, Barton F., Burton, Dennis R.
Format: Article
Language:English
Subjects:
AIDS Vaccines - immunology
Animals
Antibodies
Antiretroviral agents
Antiretroviral drugs
Clinical Trials as Topic
gag Gene Products, Human Immunodeficiency Virus - genetics
gag Gene Products, Human Immunodeficiency Virus - immunology
Genomes
Health problems
HIV
HIV Envelope Protein gp120 - genetics
HIV Envelope Protein gp120 - immunology
HIV Infections - prevention & control
HIV Infections - therapy
HIV Protease - genetics
HIV Protease - immunology
Human immunodeficiency virus
Humans
Immunogenicity, Vaccine
Infections
Lentivirus
Life cycle engineering
Mice
Neutralizing
PERSPECTIVES
Protein Multimerization
Retarding
Retroviridae
Sole
T-Lymphocytes, Cytotoxic - immunology
Vaccination
Vaccines
Vaccines, Synthetic - immunology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 2015, 17 million HIV-infected individuals worldwide were on antiretroviral drug therapies, which are remarkably effective in suppressing the virus. Yet, 6000 people a day became newly infected, making the quest for an effective and safe HIV vaccine a major global priority. However, developing a vaccine has been difficult for reasons related to the nature of the virus and its life cycle, including early integration into the host genome and the highly glycosylated, compact, and sequence-variable nature of the envelope (Env) "spike" that is the sole target of neutralizing antibodies (and typically associated with vaccine protection). Where are we, then, on the path to a vaccine?
ISSN:0036-8075
1095-9203
DOI:10.1126/science.aan0662